Press Releases

• Lonza’s new cell culture media system is designed to optimize the production of therapeutic monoclonal antibodies

• The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production

• The chemically defined, animal component-free system is scalable, from cell line development through bioprocess manufacturing

   

  Basel, Switzerland, 17 July 2023 – Lonza has launched the TheraPRO^® CHO Media System, a new cell culture platform that simplifies processes and optimizes productivity and protein quality when used with GS-CHO cell lines. The launch supports pharmaceutical and biotechnology companies manufacturing therapeutic proteins to further improve product quality while streamlining time-to-market.

  The versatility and efficiency of antibody therapeutics continues to transform the healthcare industry. To meet growing demand for such therapies, biopharmaceutical manufacturers must optimize protein production and shorten time-to-market. However, protein production can be challenging, and unexpected issues that arise during scale-up and production can increase costs and delay delivery to patients.
  

  To address these challenges, Lonza has developed the TheraPRO^® CHO Media System. The chemically defined, animal-component free, two-part production system is easy to use and simplifies media preparation. It is fully scalable and is supported by technical experts with extensive experience in troubleshooting. The TheraPRO® CHO Media System delivers efficient performance, achieving high viable cell concentrations and more than 5g/L protein titer during a 15-day culture cycle. This represents more than double the protein titer that can be produced using existing solutions on the market. 
  

  Deirdre Raduns, Senior Global Product Manager, Bioscience, Lonza, commented: “Manufacturing high-quality biologics is a complex challenge, and doing so at scale and speed is even harder. The TheraPRO^® CHO Media System leverages decades of GS-CHO cell culture expertise to address these challenges — offering notable performance through a simplified, two-part production system. With this launch, we are continuing our mission to help customers bring their life-changing therapies to market, faster.”
  

  Dr. Harsh Amin, Associate Director and Head of Protein Expression Media R&D, Bioscience, Lonza commented: “We have developed a media system that brings ease-of-use while providing high titers and product quality. As the media system is designed to be versatile, it can be used with a variety of GS Knockout CHO cell hosts, and it supports diverse clones with different metabolic profiles.”
  

  All components of the new system are manufactured in ISO 13485 certified facilities in accordance with good manufacturing practices (GMP), ensuring full product traceability and optimum lot-to-lot consistency. TheraPRO^® CHO Media System customers will receive a Drug Master File (DMF) and expert technical assistance with regulatory submissions to maximize their chances of success.
  

  For more information on the TheraPRO^® CHO Media System, please visit www.lonza.com/therapro. 

  Disclaimer

  Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this media advisory due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this media advisory. All trademarks belong to Lonza, and are registered in USA, EU or CH or belong to third party owners and are used only for informational purposes.